Sökning: onr:"swepub:oai:DiVA.org:umu-199833" >
Real-world Treatmen...
-
Bjartell, AndersLund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Urological cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital
(författare)
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
Elsevier,2022
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-199833
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-199833URI
-
https://doi.org/10.1016/j.euros.2022.08.018DOI
-
https://lup.lub.lu.se/record/584e9dd4-9a9d-4af2-8c37-2674f5fe9d16URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: Prostate cancer has a multifaceted treatment pattern. Evidence is lacking for optimal treatment sequences for metastatic castration-resistant prostate cancer (mCRPC).Objective: To increase the understanding of real-world treatment pathways and outcomes in patients with mCRPC.Design, setting, and participants: A prospective, noninterventional, real-world analysis of 3003 patients with mCRPC in the Prostate Cancer Registry (PCR; NCT02236637) from June 14, 2013 to July 9, 2018 was conducted.Intervention: Patients received first- and second-line hormonal treatment and chemotherapy as follows: abiraterone acetate plus prednisone (abiraterone)-docetaxel (ABI-DOCE), abiraterone-enzalutamide (ABI-ENZA), abiraterone–radium-223 (ABI-RAD), docetaxel-abiraterone (DOCE-ABI), docetaxel-cabazitaxel (DOCE-CABA), docetaxel-enzalutamide (DOCE-ENZA), and enzalutamide-docetaxel (ENZA-DOCE).Outcome measurements and statistical analysis: Baseline patient characteristics, quality of life, mCRPC treatments, and efficacy outcomes (progression and survival) were presented descriptively.Results and limitations: Data from 727 patients were eligible for the analysis (ABI-DOCE n = 178, ABI-ENZA n = 99, ABI-RAD n = 27, DOCE-ABI n = 191, DOCE-CABA n = 74, DOCE-ENZA n = 116, and ENZA-DOCE n = 42). Demographics and disease characteristics among patients between different sequences varied greatly. Most patients who started on abiraterone or enzalutamide stopped therapy because of disease progression. No randomisation to allow treatment/sequence comparisons limited this observational study.Conclusions: The real-world PCR data complement clinical trial data, reflecting more highly selected patient populations than seen in routine clinical practice. Baseline characteristics play a role in mCRPC first-line treatment selection, but other factors, such as treatment availability, have an impact. Efficacy observations are limited and should be interpreted with caution.Patient summary: Baseline characteristics appear to have a role in the first-line treatment selection of metastatic castration-resistant prostate cancer in the real-world setting. First-line abiraterone acetate plus prednisone seems to be the preferred treatment option for older patients and those with lower Gleason scores, first-line docetaxel for younger patients and those with more advanced disease, and first-line enzalutamide for patients with fewer metastases and more favourable performance status. The benefit to patients from these observations remains unknown.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Costa, LuisOncology Division, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal; Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal,University of Lisbon
(författare)
-
Kramer, GeroDepartment of Urology, Medical University of Vienna, Vienna, Austria
(författare)
-
Zurawski, BogdanCentrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy, Dzial Onkologii Klinicznej, Ambulatorium Chemioterapii, Bydgoszcz, Poland
(författare)
-
Galli, LucaPisana University Hospital, Pisa, Italy,University Hospital of Pisa
(författare)
-
Werbrouck, PatrickAZ Groeninge, Kortrijk, Belgium,Algemeen Ziekenhuis Groeninge
(författare)
-
Ecke, ThorstenHelios Klinikum Bad Saarow, Bad Saarow, Germany
(författare)
-
Parikh, OmiRoyal Blackburn Hospital, Blackburn, United Kingdom
(författare)
-
Bennamoun, MostefaInstitut Mutualiste Montsouris, Paris, France
(författare)
-
Garcia Freire, CamiloHospital Clínico Universitario de Santiago, Servicio de Urología, Santiago de Compostela, Spain,Complejo Hospitalario Universitario de Santiago
(författare)
-
Peer, AvivitRambam Medical Center, Haifa, Israel
(författare)
-
Ljungberg, Börje,Professor,1949-Umeå University,Umeå universitet,Urologi och andrologi(Swepub:umu)bolj0001
(författare)
-
Cicin, IrfanTrakya University Hospital, Medical Oncology Department, Edirne, Turkey
(författare)
-
Smith, EmmaJanssen-Cilag, High Wycombe, United Kingdom
(författare)
-
Lukac, MartinParexel International Czech Republic sro, on behalf of Janssen Pharmaceutica NV, Beerse, Belgium
(författare)
-
Wapenaar, RobertJanssen-Cilag BV, Breda, Netherlands
(författare)
-
Chowdhury, SimonGuy's and St Thomas’ NHS Foundation Trust and Sarah Cannon Research Institute, London, United Kingdom
(författare)
-
Avdelningen för translationell cancerforskningInstitutionen för laboratoriemedicin
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European Urology Open Science: Elsevier45, s. 12-222666-16912666-1683
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bjartell, Anders
-
Costa, Luis
-
Kramer, Gero
-
Zurawski, Bogdan
-
Galli, Luca
-
Werbrouck, Patri ...
-
visa fler...
-
Ecke, Thorsten
-
Parikh, Omi
-
Bennamoun, Moste ...
-
Garcia Freire, C ...
-
Peer, Avivit
-
Ljungberg, Börje ...
-
Cicin, Irfan
-
Smith, Emma
-
Lukac, Martin
-
Wapenaar, Robert
-
Chowdhury, Simon
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
European Urology ...
- Av lärosätet
-
Umeå universitet
-
Lunds universitet